Lupin receives USFDA approval for Brimonidine Tartrate Ophthalmic Solution, 0.1%

Brimonidine Tartrate Ophthalmic Solution, 0.1% is an alpha adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure

Mastek and Onyx Health partner to accelerate healthcare data interoperability

The partnership will provide health plans with an out-of-the-box compliance solution for CMS-9115 and CMS-0057 rules

Alembic receives FDA final approval for Betamethasone Valerate Foam, 0.12%

BI Sky Global successfully completes FDA MoCRA registration

MoCRA mandates that all facilities involved in the manufacturing and processing of cosmetic products for sale in the United States

Oblique Therapeutics and Eli Lilly to apply the AbiProt technology to generate antibodies to a high-value target

This partnership aims to accelerate research and development into innovative treatments and, if successful, will generate milestones and royalties

HearClear partners with Neuberg Diagnostics to create integrated hearing care ecosystem

The brand will establish an integrated hearing care ecosystem at Neuberg Diagnostics centers across the length and breadth of the country

Roche responds to WHO’s declaration of health emergency due to mpox outbreak

Roche confirms that its cobas MPXV test, as well as the LightMix research use only kits, detect the latest mpox virus variants

Antara AGEasy celebrates one year of advancing senior health solutions

AGEasy has made significant strides in addressing the pressing health concerns of seniors in India

Health Minister Nadda inaugurates ‘First Policy Makers’ Forum’ in New Delhi

These digital initiatives are expected to enhance the accessibility and efficiency of drug safety monitoring and standards compliance

Lupin receives USFDA’s tentative approval for Brimonidine Tartrate Ophthalmic Solution

Brimonidine Tartrate Ophthalmic Solution, 0.025% (OTC) is indicated to relieve redness of the eye due to minor eye irritations.